International Deals

My time has been spent in ?Europe.? In the last two days, I have been to Italy four times, London and France each twice and made brief stops in Germany and Switzerland. The series of meetings that I have had with European companies has caused me to come to the conclusion that companies in that region are undervalued, undermanaged, underappreciated and unhappy with the lack of availabe capital. The companies are therefore looking to gain additional investor support from US venture capitalists. At

By | January 12, 2006

My time has been spent in ?Europe.? In the last two days, I have been to Italy four times, London and France each twice and made brief stops in Germany and Switzerland. The series of meetings that I have had with European companies has caused me to come to the conclusion that companies in that region are undervalued, undermanaged, underappreciated and unhappy with the lack of availabe capital. The companies are therefore looking to gain additional investor support from US venture capitalists. At the same time, European venture capitalists are expressing concern with the inability to find local IPO exits for many of their companies and are looking to the US to find better investees. Anonymous Quote of the Day: ?A good biotech CEO is like a bullfighter: he possesses agility, grace, courage to stare danger in the face and only the remote prospect of being paid well if he survives.?

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Human Cord Plasma Protein Boosts Cognitive Function in Older Mice
AAAS